SPECT/CT quantification of ¹⁷⁷Lu for dosimetry in radionuclide therapy treatments of neuroendocrine tumors
Peptide receptor radionuclide therapy (PRRT) shows promising results in the treatment of neuroendocrine tumors. These tumors over-express somatostatin receptors that allow us to label somatostatin analogues with ¹⁷⁷Lu to deliver dose to the tumor. However, currently every patient receives the same...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2016
|
| Online Access: | http://hdl.handle.net/2429/56822 |